We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-14.07%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.34B
AUM Growth
-$421M
Cap. Flow
+$11.7M
Cap. Flow %
0.5%
Top 10 Hldgs %
40.93%
Holding
221
New
9
Increased
52
Reduced
52
Closed
18

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$15.4M
2
MDT icon
Medtronic
MDT
+$13.3M
3
UNH icon
UnitedHealth
UNH
+$8.16M
4
ISRG icon
Intuitive Surgical
ISRG
+$7.42M
5
PFE icon
Pfizer
PFE
+$7.12M

Top Sells

Rank Stock Value
1
AET
Aetna Inc
AET
+$17M
2
AZN icon
AstraZeneca
AZN
+$11.3M
3
IDXX icon
Idexx Laboratories
IDXX
+$10.4M
4
VTRS icon
Viatris
VTRS
+$8.21M
5
OHI icon
Omega Healthcare
OHI
+$6.92M

Sector Composition

Rank Sector Weight
1 Healthcare 94.39%
2 Real Estate 2.48%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DOC icon
151
Healthpeak Properties
DOC
$15.2B
$1.27M 0.05%
45,500
– –
ITCI
152
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$1.25M 0.05%
110,193
+75,343
+216% +$1.22M
OVID icon
153
Ovid Therapeutics
OVID
$442M
$1.2M 0.05%
496,977
-38,847
-7% -$177K
AKBA icon
154
Akebia Therapeutics
AKBA
$362M
$1.18M 0.05%
213,942
-52,670
-20% -$412K
HR icon
155
Healthcare Realty
HR
$7.46B
$1.16M 0.05%
46,000
– –
DERM
156
DELISTED
Dermira, Inc.
DERM
$1.16M 0.05%
161,579
-72,621
-31% -$795K
ARDX icon
157
Ardelyx
ARDX
$1.25B
$1.14M 0.05%
639,370
– –
NITE
158
DELISTED
Nightstar Therapeutics plc American Depositary Shares
NITE
$1.14M 0.05%
98,929
-51,071
-34% -$680K
BOLD
159
DELISTED
Audentes Therapeutics, Inc
BOLD
$1.12M 0.05%
52,574
+13,834
+36% +$357K
GHDX
160
DELISTED
Genomic Health, Inc.
GHDX
$1.12M 0.05%
17,370
-17,370
-50% -$1.22M
QURE icon
161
uniQure
QURE
$2.93B
$1.09M 0.05%
37,741
– –
NVAX icon
162
Novavax
NVAX
$1.22B
$1.05M 0.05%
28,550
– –
LIVN icon
163
LivaNova
LIVN
$4.45B
$1.04M 0.04%
11,400
+5,113
+81% +$549K
SPPI
164
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$1M 0.04%
114,670
– –
TTPH
165
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$971K 0.04%
42,966
– –
SNDX icon
166
Syndax Pharmaceuticals
SNDX
$1.73B
$890K 0.04%
200,000
– –
MNK
167
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$847K 0.04%
53,600
– –
EVH icon
168
Evolent Health
EVH
$358M
$841K 0.04%
42,150
-42,150
-50% -$975K
NVCR icon
169
NovoCure
NVCR
$1.77B
$820K 0.04%
+24,500
New +$896K
IMGN
170
DELISTED
Immunogen Inc
IMGN
$807K 0.03%
168,190
– –
HOLX
171
DELISTED
Hologic
HOLX
$803K 0.03%
19,546
– –
AFMD
172
DELISTED
Affimed
AFMD
$790K 0.03%
25,400
– –
TRIL
173
DELISTED
Trillium Therapeutics Inc.
TRIL
$763K 0.03%
446,099
-22,300
-5% -$66.9K
MDGL icon
174
Madrigal Pharmaceuticals
MDGL
$11.4B
$752K 0.03%
6,670
– –
ARQL
175
DELISTED
Arqule Inc
ARQL
$693K 0.03%
250,000
– –
5 6
7
8 9

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2018 Portfolio in Review

As of Q4 2018, Tekla Capital Management held 221 positions worth $2.34B, down 15% from $2.76B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Tekla Capital Management's Q4 2018 filing shows 9 new, 52 increased, 52 reduced and 18 closed positions. Its largest new stake was Wellcare Health Plans, Inc.: 13,000 shares worth $3.07M. The largest sale was Aetna Inc, an estimated $17M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 94% a quarter earlier, followed by Real Estate and Financials.

  • Tekla Capital Management's largest Q4 2018 buy was Wellcare Health Plans, Inc.: 13,000 shares worth $3.07M.
  • Tekla Capital Management added most to Bristol-Myers Squibb in Q4 2018, an estimated $15.4M increase.
  • Tekla Capital Management's biggest Q4 2018 reduction was AstraZeneca, cutting an estimated $11.3M.
  • Tekla Capital Management fully exited Aetna Inc in Q4 2018, selling an estimated $17M.
  • Tekla Capital Management's ten largest holdings make up 41% of its $2.34B portfolio in Q4 2018.
  • Tekla Capital Management opened 9 new positions and closed 18 in Q4 2018.
  • Tekla Capital Management's portfolio value fell 15% quarter-over-quarter to $2.34B.

Based on Tekla Capital Management's 13F filing for Q4 2018, filed 13 Feb 2019.